good post and it just forced me to start looking (again) over at the NYAS website for Dr. Rolf Brekkens next appearance at NYAS and can't seem to find anything and also can't find any webcast replay from the one you mentioned re: Dr. Rolf Brekken publicly stated the results of the Phase IIb NSCLC were actually better than reported due to the sabotage in a Q/A session.
I think any and all "immunotherapy" type presentations will be important moving forward, because at anytime during a Q/A session at the end, someone at sometime is bound to ask the question "Have you considered collaborations with Peregrine Pharmaceuticals and combining with a PS Targeting Mab such as bavituximab, in order to realize how much improvement there is in ORR?"
I hope it is asked, because if any collaborator may be under a gag order not to speak possibly? and if one is asked that question I would think they really can't say "no" but may be forced to say "unable to comment.."
--------------------------------------
Tuesday, January 27, 2015 | 8:30 AM - 4:30 PM Cytokine-Based Immunotherapies Keynote Speaker: James W. Mier (Beth Israel Deaconess Medical Center/ Harvard Medical School, Boston, MA) Speakers: Stephen D. Gillies (Provenance Biopharmaceuticals, Carlisle, MA), Dario Neri (Philogen, Zurich, Switzerland), Jerome Ritz (Harvard Medical School), Gilles Uzé (Université Montpellier II, Montpellier, France), K. Dane Wittrup (Massachusetts Institute of Technology, Cambridge, MA)
Systemic toxicity currently prevents exploiting the potential of many cytokines to treat cancer, viral infections, inflammatory and autoimmune conditions. Targeted delivery of immune-stimulatory or immune-regulatory cytokines offers much promise.
Wonderfully illuminating CP! Do you dictate these epistles because they seem so comprehensive that typing them out most be laborious!
You mentioned that 2016 was your target year for PPHM to get really rolling. I really like that, however, your prediction that "I think a Liver deal is EMINENT" (203638) is much more gratifying because of the "eminent" (imminent) part. A Bayer deal might be sending the rocket off earlier than 2016...?
News 
Market Data 
Discover 
